Physician profile
James Thomas Barker
NPI 1922189927
$2,141,190.70
in general payments reported to CMS, 2019-2025
41 companies · $509K in 2025
The $509K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274K · 2020: $133K · 2021: $190K · 2022: $235K · 2023: $373K · 2024: $428K · 2025: $509K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $916K · Consulting Fee: $184K · Travel and Lodging: $98K · Honoraria: $79K · Food and Beverage: $33K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $915,533.00 |
| Consulting Fee | $183,503.75 |
| Travel and Lodging | $98,069.28 |
| Honoraria | $79,315.00 |
| Food and Beverage | $33,217.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $658,361.99 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Janssen Pharmaceuticals, INC | $531,620.48 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $237,054.92 | 2019-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $234,211.20 | 2022-2025 | Auvelity, Sunosi |
| Abbvie INC. | $133,410.44 | 2021-2025 | Vraylar |
| Allergan, INC. | $128,396.38 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $116,506.82 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45,624.95 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $39,205.40 | 2019-2025 | Rexulti, Abilify Asimtufii, Nuedexta |
| Eli Lilly and Company | $7,393.07 | 2025 | |
| Bausch Health US, LLC | $1,780.17 | 2019-2025 | Aplenzin, Wellbutrin |
| Teva Pharmaceuticals USA, INC. | $1,002.16 | 2020-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $992.48 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $906.58 | 2019-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $879.82 | 2019-2025 | Fanapt, Hetlioz |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $725.55 | 2021-2025 | Azstarys |
| Lundbeck LLC | $673.85 | 2019-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $602.00 | 2021-2025 | Qelbree, Qelbree |
| Acadia Pharmaceuticals INC | $329.84 | 2019-2024 | Nuplazid |
| Indivior INC. | $222.84 | 2023-2024 | Perseris |
| Eisai INC. | $187.06 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $168.77 | 2022-2024 | Quviviq |
| Avanir Pharmaceuticals, INC. | $167.40 | 2019-2021 | |
| Neos Therapeutics, Lp | $109.77 | 2020-2022 | |
| Novo Nordisk INC | $103.90 | 2019-2024 | Wegovy, Saxenda |
| Noven Therapeutics, LLC | $96.72 | 2021-2025 | Secuado, Xelstrym |
| Tris Pharma INC | $79.21 | 2019-2024 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $73.12 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $72.75 | 2019-2022 | |
| Luye Pharma (USA) Ltd. | $51.61 | 2025 | Erzofri Extended-Release |
| Adlon Therapeutics L.P. | $39.37 | 2019-2020 | |
| Almatica Pharma LLC | $26.55 | 2021 | |
| Alfasigma USA, INC. | $24.93 | 2022 | |
| Celgene Corporation | $21.13 | 2025 | Cobenfy |
| Lilly USA, LLC | $19.60 | 2025 | Amyvid, Kisunla |
| Sun Pharmaceutical Industries INC. | $19.42 | 2021 | |
| Neuronetics, INC. | $14.48 | 2020 | |
| Shire North American Group INC | $13.97 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Barker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.